皮癬菌症/甲癬治療市場規模、佔有率、成長分析（按產品類型、給藥途徑、治療類型、分銷管道和地區分類）—產業預測（2026-2033年）

全球皮癬菌甲癬治療市場規模預計在 2024 年達到 52.8 億美元，從 2025 年的 56.9 億美元成長到 2033 年的 103.8 億美元，在預測期（2026-2033 年）內複合年成長率為 7.8%。

全球皮癬菌性甲癬治療市場正因人口趨勢、臨床需求和技術創新等多方面因素而不斷發展。老年人口的成長（老年人更容易感染灰指甲）是推動市場成長的重要因素。此外，糖尿病發生率的上升會損害免疫反應和周邊血液循環，從而增加甲癬的風險。人們對足部衛生的日益重視以及社會對指甲美觀的壓力也推動了對有效治療方法的需求。包括全身外用溶液等改進的藥物輸送系統在內的技術進步正在提高治癒率。遠距皮膚病學和行動醫療醫療的引入也使得診斷速度更快，尤其是在偏遠地區。此外，新興市場醫療保健服務的普及和各種創新治療方法的出現，正在拓展治療選擇，提高病患的滿意度和舒適度。

推動全球皮癬菌甲癬治療市場發展的因素

全球皮癬菌甲癬治療市場的主要促進因素之一是真菌性甲癬感染疾病的上升，而這又歸因於人口老齡化、久坐少動的生活方式以及糖尿病和免疫力缺乏低下等疾病發病率的增加。此外，人們對皮膚和指甲健康的日益重視，以及口服藥物、外用藥物和雷射療法等先進治療方案的廣泛應用，也推動了市場成長。自我治療的趨勢日益成長，以及非處方藥的開發，也促使越來越多的消費者尋求有效治療這種常見疾病的方法。

限制全球皮癬菌甲癬治療市場的因素

全球皮癬菌甲癬治療市場的主要限制因素之一是真菌病原體抗藥性的日益增強。這種抗藥性的增加使治療通訊協定複雜化，降低了現有抗真菌藥物的療效，並可能導致治療失敗。患者可能需要更昂貴、更具侵入性的治療來對抗抗藥性菌株，從而增加醫療成本，並阻礙患者及時就醫。此外，對甲癬症狀和治療方案缺乏了解可能導致漏診和治療不足，進一步限制了市場成長，並影響了這種常見真菌感染疾病的治療效果。

全球皮癬菌症/甲癬治療市場趨勢

全球皮癬菌甲癬治療市場正經歷著局部和非侵入性治療方法的顯著轉變，這主要源於患者對更安全、更便捷且全身副作用更少的治療方案的需求，而傳統口服藥物則不具備這些優勢。藥物遞送系統的創新，尤其是指甲油和水溶性製劑，正在提升治療效果並提高患者的依從性。新型局部用藥產品的推出以及非處方藥（OTC）治療方案的增加，尤其是在新興市場，進一步強化了這一趨勢，滿足了人們對便捷型真菌性感染疾病治療方案的需求，並顯著擴大了治療的可及性。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術評估
• 監管環境
• 客戶和購買標準分析
• 原料分析

全球皮癬菌甲癬治療市場規模（按產品類型和複合年成長率分類）（2026-2033 年）

• 藥片
• 指甲油/指甲漆
• 外用乳霜/溶液
• 其他劑型

全球皮癬菌甲癬治療市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 口服
• 外用

全球皮癬菌症/甲癬治療市場規模（按治療方法類型和複合年成長率分類）（2026-2033 年）

• 處方箋
• 非處方藥

全球皮癬菌甲癬治療市場規模（按分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院/診所
• 零售藥房
• 網路藥房

全球皮癬菌症/甲癬治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• GSK plc
• Bausch Health Companies Inc.
• Pfizer Inc.
• Galderma SA
• Johnson & Johnson Health Care Systems Inc.
• Cipla Limited
• Kaken Pharmaceutical Co., Ltd.
• Moberg Pharma AB
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Abbott Laboratories
• Merck & Co., Inc.
• Sandoz
• Eisai Co., Ltd.
• Sanofi SA
• Pfizer
• Hikma Pharmaceuticals PLC

結論與建議

Global Dermatophytic Onychomycosis Treatment Market size was valued at USD 5.28 Billion in 2024 and is poised to grow from USD 5.69 Billion in 2025 to USD 10.38 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The global market for dermatophytic onychomycosis treatment is evolving due to a blend of demographic trends, clinical needs, and technological innovations. An increase in the elderly population, predisposed to nail fungal infections, significantly drives market growth. Additionally, the rise in diabetes incidences contributes to higher onychomycosis risk by compromising immune responses and peripheral blood flow. Growing awareness of foot hygiene and societal pressures regarding nail aesthetics further elevate demand for effective treatments. Technological advancements, including enhanced drug delivery systems like penetrating topical solutions, improve cure rates. The adoption of teledermatology and mobile health also facilitates timely diagnoses, particularly in remote areas. Furthermore, expanding healthcare access in emerging markets and innovative treatment modalities diversify options, boosting patient satisfaction and comfort.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dermatophytic Onychomycosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dermatophytic Onychomycosis Treatment Market Segments Analysis

Global Dermatophytic Onychomycosis Treatment Market is segmented by Product Type, Route of Administration, Treatment Type, Distribution Channel and region. Based on Product Type, the market is segmented into Tablets, Nail paints / lacquers, Topical creams/solutions and Other delivery forms. Based on Route of Administration, the market is segmented into Oral and Topical. Based on Treatment Type, the market is segmented into Prescription and Over-the-Counter (OTC). Based on Distribution Channel, the market is segmented into Hospitals / Clinics, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dermatophytic Onychomycosis Treatment Market

One of the key market drivers for the global dermatophytic onychomycosis treatment market is the increasing prevalence of nail fungal infections attributed to factors such as aging populations, sedentary lifestyles, and rising incidences of diabetes and immunocompromised conditions. Additionally, heightened awareness of skin and nail health, combined with the growing availability of advanced treatment options including oral medications, topical therapies, and laser treatments, is propelling market growth. The rise in self-medication trends and the development of over-the-counter products further contribute to an expanding consumer base seeking effective solutions for this prevalent condition.

Restraints in the Global Dermatophytic Onychomycosis Treatment Market

One key market restraint for the global dermatophytic onychomycosis treatment market is the rising incidence of drug resistance among fungal pathogens. This growing resistance can complicate treatment protocols, rendering existing antifungal medications less effective and leading to treatment failures. Patients may require more expensive and invasive therapies to combat resistant strains, contributing to increased healthcare costs and potentially deterring patients from seeking timely medical intervention. Moreover, the lack of awareness regarding onychomycosis symptoms and treatment options may lead to underdiagnosis and inadequate treatment, further limiting market growth and patient outcomes in managing this prevalent fungal infection.

Market Trends of the Global Dermatophytic Onychomycosis Treatment Market

The global dermatophytic onychomycosis treatment market is witnessing a notable shift towards topical and non-invasive therapies, driven by patient preferences for safer and more convenient options with reduced systemic side effects compared to traditional oral medications. Innovations in drug delivery systems, particularly in nail lacquers and water-soluble formulations, are enhancing therapeutic effectiveness and encouraging greater patient compliance. This trend is further bolstered by the introduction of new topical products and a growing presence of over-the-counter (OTC) treatment options, particularly in emerging markets, significantly expanding accessibility and catering to the demand for user-friendly solutions in fungal nail infections.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape
• Customer & Buying Criteria Analysis
• Raw Material Analysis

Global Dermatophytic Onychomycosis Treatment Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Tablets
• Nail paints / lacquers
• Topical creams/solutions
• Other delivery forms

Global Dermatophytic Onychomycosis Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Topical

Global Dermatophytic Onychomycosis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Prescription
• Over-the-Counter (OTC)

Global Dermatophytic Onychomycosis Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospitals / Clinics
• Retail Pharmacies
• Online Pharmacies

Global Dermatophytic Onychomycosis Treatment Market Size & CAGR (2026-2033)

• North America (Product Type, Route of Administration, Treatment Type, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Route of Administration, Treatment Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Route of Administration, Treatment Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Route of Administration, Treatment Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Route of Administration, Treatment Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GSK plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Health Care Systems Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kaken Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moberg Pharma AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations